This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The deal brings significant exposure to the large healthcare vertical as GPN continues to focus on software-centric growth opportunities.
Good day. My name is Karnesia, and I will be your conference operator today. At this time, I would like to welcome everyone to the ACI Worldwide Reports Q2 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. Please limit your question to one question and one follow-up question. [Operator Instructions].
Global Payments Inc. (GPN - Free Report) was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $111.10 –$118.30 in the past one-month time frame, witnessed a sharp increase yesterday.
CY GPN EVTC
Ladies and gentlemen, thank you for standing by and welcome to Global Payments' 2018 Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
WFC WFCNP GPN
Global Payments Inc. (GPN - Free Report) came up with second-quarter 2018 adjusted earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.22 by 5.7% and surging nearly 37% year over year.
TSS V GPN ENR ADS
Document Table of Contents UNITED STATES
We are in the thick of the second-quarter earnings season, with 265 S&P 500 companies (collectively accounting for 66.2% of the index’s total market capitalization) having already reported their quarterly numbers as of Jul 27. Per the latest Earnings Preview, total earnings of these 265 companies increased 23.6% from the same period last year on 10.1% higher revenues, with 80.8% beating EPS estimates and 72.
WU GPN WEX FLT
Ralph Lauren Corporation (RL - Free Report) reported first-quarter fiscal 2019 adjusted earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.39. The bottom-line figure also increased by 38.7% from the prior-year quarter. Notably, this marked the company’s 14th straight quarter of earnings beat. As reported by the company, Ralph Lauren posted earnings per share of $1.31, surging 82% from the year-ago figure of 72 cents.
CWH RL GPN LULU GIII
Johnson Controls International plc (JCI - Free Report) reported adjusted earnings per share of 81 cents in third-quarter fiscal 2018, beating the Zacks Consensus Estimate of 80 cents. Moreover, earnings increased 14% from 50 cents recorded in third-quarter fiscal 2017.
FOXF CWH OSK GPN JCI
Archer Daniels Midland Company (ADM - Free Report) reported robust second-quarter 2018 results, wherein the top and bottom line outpaced the Zacks Consensus Estimate. Both the metrics also increased on a year-over-year basis. Notably, this marks the company’s third straight positive earnings surprise with a second consecutive sales miss. Following the earnings announcement, shares of the company were up 4.
CLXT CWH GPN ADM SAM UNFI
The second-quarter earnings season is past the halfway mark, with 265 S&P 500 members having already released their quarterly results, according to the latest Earnings Preview. As of Jul 27, 2018, total earnings for these S&P 500 members were up 23.6% year over year on more than 10.1% higher revenues. Of these, 80.8% surpassed earnings estimates, while 72.1% beat revenue expectation. Total earnings for the S&P 500 index are likely to increase 23.
CWH CECO GPN STRA ATGE
AMETEK, Inc. (AME - Free Report) reported second-quarter 2018 adjusted earnings of 83 cents per share, beating the Zacks Consensus Estimate by 5 cents and also surpassed management’s guided range of 76-78 cents per share. Further, the figure increased 28% from the year-ago quarter and 6.4% sequentially. Net sales increased 14.1% on a year-over-year basis and 3.4% sequentially to $1.21 billion, driven by robust organic growth and strong contribution from acquisitions.
CWH MU GPN TRIP AME SRI
10h - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
11h - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
11h - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET